Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Rofecoxib, celecoxib (Celebrex), and valdecoxib (Bextra) are a subclass of nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively block the enzyme COX-2 (cyclooxygenase-2). When Merck announced the rofecoxib withdrawal, it said that its study results were not necessarily applicable to others in the COX-2 inhibitor class.

The focus now shifts to COX-2 inhibitor class